| pubmed-article:11001391 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11001391 | lifeskim:mentions | umls-concept:C1516213 | lld:lifeskim |
| pubmed-article:11001391 | lifeskim:mentions | umls-concept:C0016360 | lld:lifeskim |
| pubmed-article:11001391 | lifeskim:mentions | umls-concept:C0023413 | lld:lifeskim |
| pubmed-article:11001391 | lifeskim:mentions | umls-concept:C1527249 | lld:lifeskim |
| pubmed-article:11001391 | lifeskim:mentions | umls-concept:C0069717 | lld:lifeskim |
| pubmed-article:11001391 | lifeskim:mentions | umls-concept:C0683598 | lld:lifeskim |
| pubmed-article:11001391 | lifeskim:mentions | umls-concept:C1883712 | lld:lifeskim |
| pubmed-article:11001391 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:11001391 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:11001391 | pubmed:dateCreated | 2001-1-3 | lld:pubmed |
| pubmed-article:11001391 | pubmed:abstractText | The addition of oxaliplatin (L-OHP) to a 5-fluorouracil (5-FU)/ leucovorin (FA) regimen was retrospectively evaluated in 35 consecutive advanced colorectal cancer patients after progression of disease. L-OHP, 25 mg/m2/day, was infused from 10.00-22.00 with a peak flow at 16.00 while 5-FU, 700 mg/m2/day and FA, 150 mg/m2/day of the I-form or 300 mg/m2/day of the racemic form, from 22.00 to 10.00 with a nocturnal peak at 4.00, for 5 days every 3 weeks in 24 patients and for 4 days every 2 weeks in the other 11. Diarrhea and sensitive neuropathy were the most relevant types of toxicity (17% of patients). An objective response was achieved in 8/35 patients (23%) [95% CL 9-37], stabilization in 15 patients (43%) which included five minor responses, and progression in 12. There was no relevant difference in quality of life assessed with the EORTC QLQ C30+3 questionnaire before and after treatment. Median duration of response and median progression-free survival were 6 months; median overall survival was 11 months. This retrospective study showed that it is possible to reverse resistance to chronomodulated 5-FU by adding chronomodulated L-OHP to the previous regimen; comparison with different schedules of this combination should be performed in order to identify the best tolerated and active regimen as second-line treatment of advanced colorectal cancer. | lld:pubmed |
| pubmed-article:11001391 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11001391 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11001391 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11001391 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11001391 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11001391 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11001391 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11001391 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11001391 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11001391 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:11001391 | pubmed:issn | 0959-4973 | lld:pubmed |
| pubmed-article:11001391 | pubmed:author | pubmed-author:GiuntaSS | lld:pubmed |
| pubmed-article:11001391 | pubmed:author | pubmed-author:TerzoliEE | lld:pubmed |
| pubmed-article:11001391 | pubmed:author | pubmed-author:PugliesePP | lld:pubmed |
| pubmed-article:11001391 | pubmed:author | pubmed-author:LéviFF | lld:pubmed |
| pubmed-article:11001391 | pubmed:author | pubmed-author:GarufiCC | lld:pubmed |
| pubmed-article:11001391 | pubmed:author | pubmed-author:BrienzaSS | lld:pubmed |
| pubmed-article:11001391 | pubmed:author | pubmed-author:GiannarelliDD | lld:pubmed |
| pubmed-article:11001391 | pubmed:author | pubmed-author:CosimelliMM | lld:pubmed |
| pubmed-article:11001391 | pubmed:author | pubmed-author:AschelterA... | lld:pubmed |
| pubmed-article:11001391 | pubmed:author | pubmed-author:CaterinoMM | lld:pubmed |
| pubmed-article:11001391 | pubmed:author | pubmed-author:NisticòCC | lld:pubmed |
| pubmed-article:11001391 | pubmed:author | pubmed-author:Bertheault-Cv... | lld:pubmed |
| pubmed-article:11001391 | pubmed:author | pubmed-author:Bensmaine | lld:pubmed |
| pubmed-article:11001391 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11001391 | pubmed:volume | 11 | lld:pubmed |
| pubmed-article:11001391 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11001391 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11001391 | pubmed:pagination | 495-501 | lld:pubmed |
| pubmed-article:11001391 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:11001391 | pubmed:meshHeading | pubmed-meshheading:11001391... | lld:pubmed |
| pubmed-article:11001391 | pubmed:meshHeading | pubmed-meshheading:11001391... | lld:pubmed |
| pubmed-article:11001391 | pubmed:meshHeading | pubmed-meshheading:11001391... | lld:pubmed |
| pubmed-article:11001391 | pubmed:meshHeading | pubmed-meshheading:11001391... | lld:pubmed |
| pubmed-article:11001391 | pubmed:meshHeading | pubmed-meshheading:11001391... | lld:pubmed |
| pubmed-article:11001391 | pubmed:meshHeading | pubmed-meshheading:11001391... | lld:pubmed |
| pubmed-article:11001391 | pubmed:meshHeading | pubmed-meshheading:11001391... | lld:pubmed |
| pubmed-article:11001391 | pubmed:meshHeading | pubmed-meshheading:11001391... | lld:pubmed |
| pubmed-article:11001391 | pubmed:meshHeading | pubmed-meshheading:11001391... | lld:pubmed |
| pubmed-article:11001391 | pubmed:meshHeading | pubmed-meshheading:11001391... | lld:pubmed |
| pubmed-article:11001391 | pubmed:meshHeading | pubmed-meshheading:11001391... | lld:pubmed |
| pubmed-article:11001391 | pubmed:meshHeading | pubmed-meshheading:11001391... | lld:pubmed |
| pubmed-article:11001391 | pubmed:meshHeading | pubmed-meshheading:11001391... | lld:pubmed |
| pubmed-article:11001391 | pubmed:meshHeading | pubmed-meshheading:11001391... | lld:pubmed |
| pubmed-article:11001391 | pubmed:meshHeading | pubmed-meshheading:11001391... | lld:pubmed |
| pubmed-article:11001391 | pubmed:meshHeading | pubmed-meshheading:11001391... | lld:pubmed |
| pubmed-article:11001391 | pubmed:meshHeading | pubmed-meshheading:11001391... | lld:pubmed |
| pubmed-article:11001391 | pubmed:meshHeading | pubmed-meshheading:11001391... | lld:pubmed |
| pubmed-article:11001391 | pubmed:meshHeading | pubmed-meshheading:11001391... | lld:pubmed |
| pubmed-article:11001391 | pubmed:meshHeading | pubmed-meshheading:11001391... | lld:pubmed |
| pubmed-article:11001391 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:11001391 | pubmed:articleTitle | Overcoming resistance to chronomodulated 5-fluorouracil and folinic acid by the addition of chronomodulated oxaliplatin in advanced colorectal cancer patients. | lld:pubmed |
| pubmed-article:11001391 | pubmed:affiliation | Oncologia Medica Complementare, Istituto Regina Elena, Rome, Italy. garufi@sirio-oncology.it | lld:pubmed |
| pubmed-article:11001391 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11001391 | lld:pubmed |
